Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Provided By GlobeNewswire
Last update: Nov 13, 2025
Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026
First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing
Read more at globenewswire.com
